Zwitterionic gel encapsulation promotes protein stability, enhances pharmacokinetics, and reduces immunogenicity

Proceedings of the National Academy of Sciences of the United States of America

Volumn 112, Issue 39, 2015, Pages 12046-12051

  Zhang, Peng ^a   Sun, Fang ^a   Tsao, Caroline ^a   Liu, Sijun ^b   Jain, Priyesh ^a   Sinclair, Andrew ^a   Hung, Hsiang Chieh ^a   Bai, Tao ^a   Wu, Kan ^a   Jiang, Shaoyi ^a,b  

^a University of Washington   (United States)

^b University of Washington   (United States)

Author keywords

Hydrogel; Immune response; Nanomedicine; Protein delivery; Zwitterionic polymer

Indexed keywords

ANTIBODY; BETAINE DERIVATIVE; ENZYME ANTIBODY; PEGYLATED URICASE; POLYCARBOXYBETAINE; POLYCARBOXYBETAINE ANTIBODY; POLYMER; UNCLASSIFIED DRUG; URATE OXIDASE; URICASE ANTIBODY; BETAINE; GEL; PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG HALF LIFE; ENCAPSULATION; GEL; IMMUNE RESPONSE; IMMUNOGENICITY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN MODIFICATION; PROTEIN STABILITY; RAT; ZWITTERIONIC GEL ENCAPSULATION; ANIMAL; CHEMISTRY; HALF LIFE TIME; NANOMEDICINE; PHARMACOKINETICS; PROCEDURES; THERAPEUTIC USE;

ANIMALS; BETAINE; GELS; HALF-LIFE; NANOMEDICINE; PROTEIN STABILITY; PROTEINS; RATS; URATE OXIDASE;

EID: 84942855080     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1512465112     Document Type: Article

References (37)

1. Mitragotri S, Burke PA, Langer R (2014) Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies. Nat Rev Drug Discov 13(9):655-672.
2. Shankar G, Pendley C, Stein KE (2007) A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nat Biotechnol 25(5):555-561.
3. Harris JM, Chess RB (2003) Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov 2(3):214-221.
4. Alconcel SNS, Baas AS, Maynard HD (2011) FDA-approved poly (ethylene glycol) - protein conjugate drugs. Polym Chem 2(7):1442-1448.
5. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P (2012) Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 9(11):1319-1323.
6. Abuchowski A, Van Es T, Palczuk NC, Davis FF (1977) Alteration of immunological properties of bovine serum albumin by covalent attachment of polyethylene glycol. J Biol Chem 252(11):3578-3581.
7. Richter AW, Akerblom E (1983) Antibodies against polyethylene glycol produced in animals by immunization with monomethoxy polyethylene glycol modified proteins. Int Arch Allergy Appl Immunol 70(2):124-131.
8. Hershfield MS, et al. (2014) Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients. Arthritis Res Ther 16(2):R63.
9. Lipsky PE, et al. (2014) Pegloticase immunogenicity: The relationship between efficacy and antibody development in patients treated for refractory chronic gout. Arthritis Res Ther 16(2):R60.
10. Armstrong JK, et al. (2007) Antibody against poly (ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110(1):103-111.
11. Van Der Eijk AA, Vrolijk JM, Haagmans BL (2006) Antibodies neutralizing peginterferon alfa during retreatment of hepatitis C. N Engl J Med 354(12):1323-1324.
12. Ishida T, Kiwada H (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int J Pharm 354(1-2):56-62.
13. Shiraishi K, et al. (2013) Hydrophobic blocks of PEG-conjugates play a significant role in the accelerated blood clearance (ABC) phenomenon. J Control Release 165(3):183-190.
14. Armstrong JK, et al. (2003) Occurrence of an antibody to poly (ethylene glycol) in normal donors. Blood 102(11):556A.
15. Saifer MG, Williams LD, Sobczyk MA, Michaels SJ, Sherman MR (2014) Selectivity of binding of PEGs and PEG-like oligomers to anti-PEG antibodies induced by methoxyPEG-proteins. Mol Immunol 57(2):236-246.
16. Schneck E, Berts I, Halperin A, Daillant J, Fragneto G (2015) Neutron reflectometry from poly (ethylene-glycol) brushes binding anti-PEG antibodies: Evidence of ternary adsorption. Biomaterials 46:95-104.
17. Sherman MR, Williams LD, Sobczyk MA, Michaels SJ, Saifer MG (2012) Role of the methoxy group in immune responses to mPEG-protein conjugates. Bioconjug Chem 23(3):485-499.
18. Jiang S, Cao Z (2010) Ultralow-fouling, functionalizable, and hydrolyzable zwitterionic materials and their derivatives for biological applications. Adv Mater 22(9):920-932.
19. Smith RS, et al. (2012) Vascular catheters with a nonleaching poly-sulfobetaine surface modification reduce thrombus formation and microbial attachment. Sci Transl Med 4(153):153ra132.
20. Moro T, et al. (2004) Surface grafting of artificial joints with a biocompatible polymer for preventing periprosthetic osteolysis. Nat Mater 3(11):829-836.
21. Ladd J, Zhang Z, Chen S, Hower JC, Jiang S (2008) Zwitterionic polymers exhibiting high resistance to nonspecific protein adsorption from human serum and plasma. Biomacromolecules 9(5):1357-1361.
22. Zhang L, et al. (2013) Zwitterionic hydrogels implanted in mice resist the foreign-body reaction. Nat Biotechnol 31(6):553-556.
23. Yang W, et al. (2014) Poly (carboxybetaine) nanomaterials enable long circulation and prevent polymer-specific antibody production. Nano Today 9(1):10-16.
24. Bai T, et al. (2014) Restraint of the differentiation of mesenchymal stem cells by a nonfouling zwitterionic hydrogel. Angew Chem Int Ed Engl 53(47):12729-12734.
25. Nguyen TH, et al. (2013) A heparin-mimicking polymer conjugate stabilizes basic fibroblast growth factor. Nat Chem 5(3):221-227.
26. Keefe AJ, Jiang S (2012) Poly (zwitterionic) protein conjugates offer increased stability without sacrificing binding affinity or bioactivity. Nat Chem 4(1):59-63.
27. Wei W, et al. (2013) Construction of robust enzyme nanocapsules for effective organophosphate decontamination, detoxification, and protection. Adv Mater 25(15):2212-2218.
28. Yan M, Ge J, Liu Z, Ouyang P (2006) Encapsulation of single enzyme in nanogel with enhanced biocatalytic activity and stability. J Am Chem Soc 128(34):11008-11009.
29. Elsabahy M, Wooley KL (2012) Design of polymeric nanoparticles for biomedical delivery applications. Chem Soc Rev 41(7):2545-2561.
30. Caliceti P, Schiavon O, Veronese FM (1999) Biopharmaceutical properties of uricase conjugated to neutral and amphiphilic polymers. Bioconjug Chem 10(4):638-646.
31. Yasuda Y, Fujita T, Takakura Y, Hashida M, Sezaki H (1990) Biochemical and biopharmaceutical properties of macromolecular conjugates of uricase with dextran and polyethylene glycol. Chem Pharm Bull (Tokyo) 38(7):2053-2056.
32. Cao Z, Jiang S (2012) Super-hydrophilic zwitterionic poly (carboxybetaine) and amphiphilic non-ionic poly (ethylene glycol) for stealth nanoparticles. Nano Today 7(5):404-413.
33. Pombo García K, et al. (2014) Zwitterionic-coated "stealth" nanoparticles for biomedical applications: Recent advances in countering biomolecular corona formation and uptake by the mononuclear phagocyte system. Small 10(13):2516-2529.
34. Zhang L, et al. (2012) Softer zwitterionic nanogels for longer circulation and lower splenic accumulation. ACS Nano 6(8):6681-6686.
35. Yang Q, et al. (2014) Evading immune cell uptake and clearance requires PEG grafting at densities substantially exceeding the minimum for brush conformation. Mol Pharm 11(4):1250-1258.
36. Majorek KA, et al. (2012) Structural and immunologic characterization of bovine, horse, and rabbit serum albumins. Mol Immunol 52(3-4):174-182.
37. Zhang Z, et al. (2008) Nonfouling behavior of polycarboxybetaine-grafted surfaces: Structural and environmental effects. Biomacromolecules 9(10):2686-2692.